Global Recombinant DNA (rDNA) Technology Market - Segmented by Product (Medical and Non-medical), Application, End-User and Geography - Growth, Trends and Forecast (2018 - 2023)
|発行||Mordor Intelligence LLP||商品コード||707232|
|出版日||ページ情報||英文 110 Pages
|世界の組換えDNA（rDNA）技術市場：製品（医薬品、非医薬品）、用途、エンドユーザー、地域別（2018年〜2023年） Global Recombinant DNA (rDNA) Technology Market - Segmented by Product (Medical and Non-medical), Application, End-User and Geography - Growth, Trends and Forecast (2018 - 2023)|
|出版日: 2018年08月01日||ページ情報: 英文 110 Pages||
The global recombinant DNA (rDNA) market is projected to grow at a CAGR of approximately 7.2% during the forecast period (2018-2023). The global recombinant DNA (rDNA) market is experiencing considerable growth due to the factors like widespread application of this genetically modified crop development, bio pesticides & biofuel production, and gene therapy, presence of biopharmaceuticals pipeline and production of various therapeutic proteins.
Increasing Demand as Well as Application of Recombinant/ Genetically Modified Products Boost the Growth of Recombinant DNA (rDNA) Technology Market
Recombinant DNA technology is performing a vital role in improving health conditions by developing new vaccines and pharmaceuticals. The treatment strategies are also improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Also many other industries are getting benefit from the Genetically Modified Organism (GMO) research. Such as micro-organisms are being considered as future clean fuel producers and bio degrader. Genetically modified vaccines are developed for curing various diseases in human and plants. The recombinant DNA technology created new opportunities for innovations to produce a wide range of therapeutic products with immediate effect in the medical genetics and biomedicine by modifying microorganisms, animals, and plants to yield medically useful substances.
Risks Pertaining to the Usage of Genetically Modified Food Hindering Recombinant DNA (rDNA) Technology Market
The genes are being transferred occur naturally in other species but there are unknown consequences to altering the natural state of an organism through gene expression. Such alterations can change the organism's metabolism, growth rate and also the response to the external environmental factors. These consequences influence the GMO but also the environment in which the organism is allowed to proliferate. Potential health risks to humans include the possibility of exposure of new allergens in genetically modified foods and also the transfer of antibiotic-resistant genes to gut flora. Thus it all these risks associated with the use of genetically modified food is hindering the growth of the market. Additionally, regulatory, scientific, and ethical challenges associated with gene therapy is also hindering the growth of the Recombinant DNA (rDNA) Market.
North America has the Largest Share in Global Recombinant DNA (rDNA) Technology Market
The largest share of North America is attributed due to the fact that there is a substantial number of biopharmaceutical manufacturing participants that are headquartered in the USA. Moreover, presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology has also driven the growth of the North America region. Also in August 2017, US FDA approved first gene therapy available in the United States which is developed for the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah for patients suffering from patients with a form of acute lymphoblastic leukemia (ALL).
Key Developments in the Recombinant DNA (rDNA) Technology Market
Jun 2018: Eli Lilly and Company acquired ARMO BioSciences.
Aug 2017: FDA approved Kymriah (tisagenlecleucel) for the treatment of advanced B-cell precursor acute lymphoblastic leukemia in patients for certain pediatric and young adult.
Major Players: AMGEN INC, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.), GENSCRIPT, MERCK KGAA, NEW ENGLAND BIOLABS, NOVARTIS AG, NOVO NORDISK A/S, PFIZER INC., and SANOFI among others.
Reasons to Purchase Recombinant DNA (rDNA) Technology Market Report
Current and future global recombinant DNA (rDNA) market outlook in the developed and emerging markets
Analyzing various perspectives of the market with the help of Porter's five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness fastest growth during the forecast period
Identify the latest developments, market shares and strategies employed by the major market players.
3-month analyst support along with the Market Estimate sheet (in Excel).
Customization of Recombinant DNA (rDNA) Technology Market Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
List Not Exhaustive